Výsledky vyhľadávania - "Rosenblatt, Joseph"

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Autor Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S

“…Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric…”
Získať plný text

B cell regulation of the anti-tumor response and role in carcinogenesis Autor Schwartz, Marc, Zhang, Yu, Rosenblatt, Joseph D.

“…The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic…”
Získať plný text

Regulatory B cells in anti-tumor immunity Autor Zhang, Yu, Gallastegui, Nicolas, Rosenblatt, Joseph D

“…Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic…”
Zistit podrobnosti o prístupe

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study Autor Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Yang, Yin, Sievers, Eric L, Kennedy, Dana A, Shustov, Andrei

“…Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug…”
Zistit podrobnosti o prístupe

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Autor Chen, Robert, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Huebner, Dirk, Fong, Abraham, Younes, Anas

“…Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin…”
Zistit podrobnosti o prístupe

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma Autor Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M, Kennedy, Dana A, Shustov, Andrei

“…This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large…”
Zistit podrobnosti o prístupe

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma Autor Younes, Anas, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Ramchandren, Radhakrishnan, Bartlett, Nancy L, Cheson, Bruce D, de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Kennedy, Dana A, Sievers, Eric L, Chen, Robert

“…Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing…”
Zistit podrobnosti o prístupe

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) Autor Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A Scott, Miao, Harry, Beygi, Sara, Jacobson, Caron A

“…Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular…”
Zistit podrobnosti o prístupe

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma Autor Gopal, Ajay K, Chen, Robert, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Chi, Xuedong, Sievers, Eric L, Younes, Anas

“…We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory…”
Zistit podrobnosti o prístupe

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution Autor Alderuccio, Juan Pablo, Zhao, Wei, Desai, Amrita, Gallastegui, Nicolas, Ramdial, Jeremy, Kimble, Erik, de la Fuente, Macarena I, Rosenblatt, Joseph D, Chapman, Jennifer R, Vega, Francisco, Reis, Isildinha M, Lossos, Izidore S

“…Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large…”
Zistit podrobnosti o prístupe

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies Autor Fanale, Michelle A, Forero-Torres, Andres, Rosenblatt, Joseph D, Advani, Ranjana H, Franklin, Anna R, Kennedy, Dana A, Han, Tae H, Sievers, Eric L, Bartlett, Nancy L

“…The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl…”
Zistit podrobnosti o prístupe

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Autor Advani, Ranjana, Forero-Torres, Andres, Furman, Richard R, Rosenblatt, Joseph D, Younes, Anas, Ren, Hong, Harrop, Kate, Whiting, Nancy, Drachman, Jonathan G

“…To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell…”
Zistit podrobnosti o prístupe

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma Autor Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.

“…Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic…”
Získať plný text

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Autor Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew L, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph D, Wulff, Jacob, Shen, Rhine R, Zhang, Wangshu, Poddar, Soumya, Miao, Harry, Nikolajeva, Olga, Jacobson, Caron A

“…Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular…”
Zistit podrobnosti o prístupe

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model Autor Tadmor, Tamar, Zhang, Yu, Cho, Hyun-Mi, Podack, Eckhard R., Rosenblatt, Joseph D.

“…Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by…”
Získať plný text

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity Autor Bhatt, Shruti, Parvin, Salma, Zhang, Yu, Cho, Hyun-Mi, Kunkalla, Kranthi, Vega, Francisco, Timmerman, John M, Shin, Seung-Uon, Rosenblatt, Joseph D, Lossos, Izidore S

“…In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly…”
Zistit podrobnosti o prístupe

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial Autor Alderuccio, Juan Pablo, Alencar, Alvaro J, Schatz, Jonathan H, Kuker, Russ A, Pongas, Georgios, Reis, Isildinha M, Lekakis, Lazaros J, Spiegel, Jay Y, Sandoval-Sus, Jose, Beitinjaneh, Amer, Stanchina, Michele D, Trabolsi, Asaad, Lossos, Izidore S, Rosenblatt, Joseph D, Lessen, David S, Moskowitz, Craig H

“…Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity…”
Zistit podrobnosti o prístupe

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Autor Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres

“…Background Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with…”
Získať plný text

Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma Autor Lossos, Izidore S., Reis, Isildinha M., Rosenblatt, Joseph D., Alderuccio, Juan Pablo

Získať plný text

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion Autor Zhang, Yu, Eliav, Yair, Shin, Seung-uon, Schreiber, Taylor H., Podack, Eckhard R., Tadmor, Tamar, Rosenblatt, Joseph D.

“…The mechanisms by which B lymphocytes inhibit anti-tumor immunity remain poorly understood. Murine EMT-6 mammary tumors grow readily in immune competent mice…”
Získať plný text